WE CLAIM:

1. A monoclonal antibody binding to a peptide comprising an amino acid sequence represented by SEQ ID NO. 1;

   further comprising:

   in a variable region of a light chain an amino acid sequence represented by positions 21-131 of SEQ ID NO 6; and

   in a variable region of a heavy chain an amino acid sequence represented by positions 20-139 of SEQ ID NO 11.

2. The monoclonal antibody of claim 1, comprising in a variable region of a light chain: CDR1 comprising an amino acid sequence represented by SEQ ID NO 2 CDR2; comprising an amino acid sequence represented by SEQ ID NO 3; and CDR3 comprising an amino acid sequence represented by SEQ ID NO 4.

3. The monoclonal antibody of claim 1, comprising in a variable region of a heavy chain: CDR1 comprising an amino acid sequence represented by SEQ ID NO 7, CDR2 comprising an amino acid sequence represented by SEQ ID NO 8, and CDR3 comprising an amino acid sequence represented by SEQ ID NO 9.

4. The monoclonal antibody of claim 1, wherein the antibody is one selected from the group consisting of a chimeric antibody, a humanized antibody and a human antibody.

5. The monoclonal antibody of claim 1, wherein the antibody is produced by a hybridoma with a deposition number of ATCC Designation: PTA-122900.
6. The monoclonal antibody of claim 1, wherein the antibody comprises an antigen-binding fragment selected from the group consisted of Fab, Fab ', (Fab') 2, Fv and scFv.
7. The monoclonal antibody of claim 1, comprising an isotype of immunoglobulin selected from the group consisted of IgG1, IgG2, IgG4, IgA, IgE and IgD.
8. An antigen-binding fragment of the monoclonal antibody of any of claims 1-7.
9. A hybridoma for producing the monoclonal antibody of any of claims 1-7 or the antigen binding fragment of claim 8, characterized by having a deposition number of ATCC Designation: PTA-122900.
10. The monoclonal antibody of any of claims 1-7 or the antigen-binding fragment of claim 8 for use as a medicament for functionally inhibiting immunosuppressive functions of a pathogen.
11. A pharmaceutical composition, comprising an effective dose of a monoclonal antibody of any of claims 1-7 or an antigen-binding fragment of claim 8.